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Abstract
The wound-healing process induced by chronic hepatitis C virus (HCV) infection triggers liver damage
characterized by fibrosis development and finally cirrhosis. Liver Transplantation (LT) is the optimal surgical
treatment for HCV-cirrhotic patients at end-stage liver disease. However, acute cellular rejection (ACR) and HCV
recurrence disease represent two devastating complications post-LT. The accurate differential diagnosis between
both conditions is critical for treatment choice, and similar histological features represent a challenge for
pathologists. Moreover, the HCV recurrence disease severity is highly variable post-LT. HCV recurrence disease
progression is characterized by an accelerated fibrogenesis process, and almost 30% of those patients develop
cirrhosis at 5-years of follow-up. Whole-genome gene expression (WGE) analyses through well-defined
oligonucleotide microarray platforms represent a powerful tool for the molecular characterization of biological
process. In the present manuscript, the utility of microarray technology is applied for the ACR and HCV-recurrence
biological characterization in post-LT liver biopsy samples. Moreover, WGE analysis was performed to identify
predictive biomarkers of HCV recurrence severity in formalin-fixed paraffin-embedded liver biopsies prospectively
collected.
Introduction
Hepatic fibrogenesis is considered a model of the wound-
healing response to chronic liver injury. This process is
characterized by extra-cellular matrix (ECM) proteins
accumulation as consequence of an imbalance between
the deposition and degradation of ECM components [1-4].
Different stimuli such as cytokines and other extracellular
signals, including reactive oxygen species (ROC) produced
by parenchymal (mainly stellate cells) and non-parenchy-
mal (mononuclear cellular infiltration) cells have been
demonstrated to be involved in the fibrogenesis response
to liver injury ([5] and references therein).
Hepatotropic viruses, especially hepatitis C (HCV)
virus, constitute the principal chronic liver injury etiology
[6]. After 15-20 years, most of HCV-chronic infected
patients will develop liver cirrhosis characterized by a dis-
tortion of the hepatic architecture and vascular structure,
and a nodular transformation of the liver surface [1,2,7].
Clinical characteristics of liver fibrosis are associated with
hepatocellular dysfunction and increased intrahepatic
resistance to blood flow leading to hepatic insufficiency
and portal hypertension, and associated hepatocellular
carcinoma (HCC) in 5% of cases [8-11]. Despite available
therapeutic protocols aimed to treat the etiological agent
(virus), stellate cells (involved in liver fibrogenesis), or
specific signaling pathways, there is no effective pharma-
ceutical intervention for liver fibrosis associated with
viral injury [5]. In this regard, HCV-cirrhotic patients at
end stage liver disease have been prominently benefi-
ciated with liver transplant (LT). Indeed, HCV induced
cirrhosis with or without HCC is the leading indication
for liver transplantation (LT) in USA, Europe and Japan
[12,13] (Figure 1).
Unfortunately, HCV recurrence is universal. HCV RNA
serum load dramatically decreases until almost undetect-
able level within 24-48 hours post-LT. However, it incre-
ments few days post-LT with a peak at 1-3 months, and
reaching a 1-2 logs plateau higher than the pre-LT viral
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load after the first year post-LT [14]. Of those patients,
about 80-100% will develop HCV recurrence disease, and
25-30% of them will course with accelerated fibrosis pro-
gression and concomitant cirrhosis development within 5
years post-LT. These patients require liver re-transplan-
tation or will develop liver failure [13]. In parallel, acute
cellular rejection (ACR) represents an additional cause of
morbidity and allograft injury in HCV-infected recipients.
Despite the rejection risk rate is controversial in HCV
patients the incidence round 40% at 6-months post-LT
as reported previously by large cohort studies [15]. Both
post-LT complications have clinical and histopathological
overlapped features turning difficult the accurate differ-
ential diagnosis, which may threat the allograft and
patient survival rate due to the opposite therapy [15-17].
The discovery of reliable biomarkers for differential diag-
nosis of both complications, and also for HCV recurrence
disease surveillance constitutes the research endeavor. The
implementation of whole-genome gene expression (WGE)
studies using microarray technology represents an out-
standing opportunity for biomarkers discovery. The pre-
sent article is focused on performed WGE analysis aimed
to differentiate ACR in the setting of HCV recurrence dis-
ease, and to predict liver fibrosis progression in HCV-
infected recipients.
ACR and HCV recurrence differential diagnosis post-LT:
the paradigm
The differential diagnosis of ACR in the setting of HCV
recurrence disease remains an important cause of mor-
bidity and late graft failure in liver-transplant recipients.
The assessment of liver allograft biopsy is still considered
to be the “gold standard“ for proper differentiation
between both post-LT conditions. However, subtle simi-
larities in the histopathology and clinical course turn dif-
ficult and uncertain the pathological differentiation, even
among experiences hepatologists [18,19]. HCV recur-
rence disease have been described in three major forms:
Acute or chronic recurrence and the less frequent and
more aggressive primary cholestatic disease called fibros-
ing cholestatic hepatitis. All of these forms course with a
characteristic lobular inflammatory cellular infiltrate [20].
ACR occurs due to the attacks of the recipient immune
system to the allograft and it is characterized by severe
inflammatory infiltrate of the portal tract with the bile
duct epithelial cells and the endothelium of hepatic
arteries and veins as major targets. The appropriate clini-
cal differentiation between both conditions directly
impact in the associated therapy decision basically by the
administration of steroid bolus for ACR treatment.
Unfortunately, the ACR therapy results contradictory for
HCV recurrence cases due to the induction of an exacer-
bation of the HCV infection accompanied by worse allo-
graft and patient survival [16,21].
The implementation of large-scale genomic analyses
strategies has provided new insights into various disease
processes and had assisted on elucidating genomic pat-
terns for mechanism, diagnosis, prognosis, and treatment
selection of complex and multi-factorial diseases [13]. For
instance, microarray technology represented a powerful
tool for the molecular understanding and knowledge of
involved gene networks and regulatory pathways for each
particular condition.
As a first approach, differentially expressed genes were
evaluated in ACR and HCV recurrence liver biopsy sam-
ples from HCV-infected recipients using oligonucleotide
GeneChip® (Affymetrix Inc., CA, USA). The study was
approved by the Institutional Review Board at Virginia
Commonwealth University, and informed consents were
obtained from all patients. The patients cohort included
liver biopsy samples from 24 HCV-recipients with histo-
logical diagnosis of HCV recurrence disease (n = 13) and
ACR in the setting of HCV (HCV-ACR; n = 11). Liver
tissue from chronic HCV-infected patients without LT
(Chronic-HCV; n = 10) were included for comparison
analysis proposes. Tissue collection, total RNA isolation
and quality control criteria, cDNA synthesis, in vitro
transcription for labeled cRNA probe, and microarray
hybridization and analysis were performed as described
previously [22]. No significant differences in patient age
and histological inflammatory activity index were identi-
fied between groups. All patients were Caucasian, male
and infected with HCV genotype 1b. From the analysis,
3747 probesets were found to be significantly differen-
tially expressed among three pairwise comparisons
(HCV-ACR vs. HCV recurrence; HCV-ACR vs. Chronic-
HCV; Chronic-HCV vs. HCV recurrence). Of those, 164
probesets were found to be differentially expressed
between HCV-ACR and HCV-recurrence alone samples.
Thirteen probe sets were found unique for both condi-
tions (Figure 2A). Gene ontology and gene interaction
analyses were performed using Ingenuity Pathways Ana-
lysis tools http://www.ingenuity.com. Those differentially
Figure 1 Schematic representation of the liver wound-healing
process in HCV infected patients. An arrowhead indicates a
hepatocellular carcinoma (HCC) lesion. MELD: Model of End Stage
Liver Disease. LT: Liver Transplantation.
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expressed genes in ACR biopsy samples were associated
with pathways involved in immune and inflammatory
responses, apoptosis, complement system, and growth
factor receptors. HCV recurrence samples revealed
predominantly gene expression patterns associated with
cell cycle and cell division, cell proliferation and blood
coagulation. The supervised hierarchical clustering analy-
sis including specific probesets differentially expressed
for HCV-ACR vs. HCV recurrence clustered all samples
in two well-differentiated groups characterizing both dif-
ferent post-LT conditions (Figure 2B). This first analysis
clearly demonstrates the potential efficacy of gene
expression analysis to differentiate ACR from HCV
recurrence post-LT [13].
In a second approach, a similar analysis was per-
formed by increasing the number of samples. A total of
51 biopsy samples from unique HCV-infected recipients
were included in the analysis. A training set composed
by 32 ACR liver samples from HCV-infected recipients
and 2 ACR liver samples from no HCV-infected recipi-
ents (n =34), were evaluated using microarray techni-
ques. From the analysis, 179 probesets were found
significantly differentially expressed among HCV-ACR,
no-HCV-ACR, and HCV recurrence biopsy samples. A
total of 71 exclusive genes were identified for HCV-
ACR vs. HCV recurrence pairwise comparison. Interest-
ingly, no significant probesets were found differentially
expressed between ACR samples from HCV and no-
HCV infected recipients, which suggest a particular
ACR molecular nature independent of the HCV infec-
tion. Gene ontology analysis identified canonical path-
ways specifically associated to a cytotoxic T cell profile
in for HCV recurrence samples, and inflammatory
response related genes as the ACR profile. The super-
vised clustering analysis including probesets (n = 80)
representing those 71 specific genes displayed two well-
differentiated groups for ACR and HCV recurrence
samples. Interestingly, no-HCV-ACR samples were clus-
tered within the HCV-ACR group (Figure 3).
In parallel, a LASSO model was fit with HCV recur-
rence vs. HCV-ACR as the dependent viable predicted,
followed of N-fold cross validation to provide an
unbiased estimate of generalization error. Interestingly,
the best fitting-LASSO model included 15 genes with an
accuracy of 100% for the training set, while the N-fold
cross-validation accuracy was of 78.1%. Four out of
those fifteen genes were also included into the exclusive
gene list, and further validated in an independent set of
19 biopsy samples (validation set) [23].
The concluding results from the analysis of both
experimental approaches using GeneChip® microarrays
Figure 2 Molecular characterization of HCV-infected liver
biopsy samples diagnosed with ACR or HCV recurrence. A.
Venn diagram illustrating a total of 3747 differentially expressed
probesets in three pairwise comparisons composed by HCV-ACR
(acute cellular rejection in HCV infected patients), HCV recurrence,
and chronic HCV liver biopsy samples. B. Heatmap and
dendrogram resulting from agglomerative hierarchical clustering
using Ward’s method, using 1-Pearson’s correlation for distance
measure.
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clearly demonstrate a differential gene expression signa-
ture between both conditions. Indeed, HCV recurrence
disease is characterized by an adhesion and apoptosis of
cytotoxic T cells profile regulated by canonical pathways
related to IFN-g and NFB, while ACR is related to
genes associated with an immediate hypersensitivity
reaction [23]. The histopathological features of both
conditions are related with mottled hepatocytes apopto-
sis with a Th-1 type profiled lobular inflammation for
HCV recurrence disease, and inflammation of the portal
tract, bile ducts and hepatic vessel endothelium charac-
terized by CD4+ and CD8+ T cells together with macro-
phages and eosinophil cells for ACR [16,24,25]. Thus,
the genomic profiles identified by this study correlate
well with the previously described cellular population
that characterized both conditions [13,23]. More impor-
tantly, it demonstrates the possibility to establish specific
biomarker panels to be combined with the conventional
histopathological assessment.
Prediction of fibrosis progression in HCV recurrence
disease
Chronic HCV-related hepatic insufficiency is associated
with decreased rates of patient and allograft survival in
comparison with other indications for liver transplantation
[26]. Different factors inherent to the donor, recipient, and
post-transplant variables have been associated with pro-
gression and severity of the liver allograft injury course in
HCV recurrence disease [13,27]. Nowadays any of those
factors were established as independent predictors of HCV
recurrence severity at early stage of the disease in HCV-
infected recipients. For instance, it became critical the
identification of reliable biomarker predictors of disease
progression at the time of HCV recurrence diagnosis since
the high variable aggressiveness of the disease.
Molecular profiling at early stages of the disease might
provide important information regarding mechanisms
involved in accelerated fibrogenesis progression as HCV
recurrence severity indicator. Even more, analysis of his-
torical liver biopsy samples represents a feasible research
scenario. In this regard, genome-wide gene expression
analysis has been performed in Formalin-Fixed Paraffin-
Embedded (FFPE) liver biopsies at the time of HCV recur-
rence diagnosis [13,28]. HCV recurrence was defined as
post-transplant increased serum level of Alanine Amino-
transferase (ALT) and positive PCR for HCV as previously
shown [28]. Progression of the disease was determined by
the fibrosis severity in FFPE biopsy samples at 36 months
post-LT (Figure 4A). Fibrosis stages were determined
using METAVIR score system [29]. A total of 42 unique
Figure 3 Supervised hierarchical clustering for HCV-ACR, ACR-
alone, and HCV recurrence diagnosed liver biopsy samples. The
dendrogram illustrates clustered samples using Ward’s method
when a total of 80 differentially expressed probesets are included.
ACR samples from no-HCV-infected recipients are highlighted in
grey boxes.
Figure 4 Molecular characterization of HCV recurrence samples
at diagnosis time for disease severity progression prediction.
A. Schematic illustration of a retrospective analysis using
prospectively collected FFPE liver biopsy samples at HCV recurrence
diagnosis (A) and 3-years of follow-up (B) as time-point for
classification. B. METAVIR score criteria used for the classification of
FFPE liver biopsy samples. Liver biopsy samples at HCV recurrence
diagnosis time were classified in three groups (G1, G2, and G3)
depending on the fibrosis severity of paired 3-years follow-up
biopsy samples. C. Dendrogram illustrating a supervised
agglomerative hierarchical clustering with 50 differentially expressed
beads identified between G1 vs. G3 using DASL assay.
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samples from 21 adult patients who underwent LT
between 1995 and 2006 were included. Samples at HCV
recurrence diagnosis time were grouped as Mild (G1;
n = 8), Intermediate (G2; n = 5), and Severe (G3; n = 8)
referred to the follow-up biopsy at 3-years post-LT (Figure
4B). The study population were composed by 25 (58%)
and 18 (42%) white male and female HCV recipients. All
patients did not receive HCV treatment, and the mean
time from LT to HCV recurrence was 5.5 ± months. The
predominant HCV genotype were 1 (84%), and 7 patients
were infected with genotypes 2 or 3. Total RNA was iso-
lated using Recover All™ Total Nucleic Acid Isolation Kit
(Ambion, Austin, TX, USA). Quality control parameters
for required RNA purity for WGE analysis have been
established and tested [28]. Differential gene expression
analysis among study groups were performed using WGE-
DASL® Assay following manual instructions (Illumina
Inc., USA). HumanRef-8 Expression BeadChips (Illumina,
Inc., USA) hybridization and followed analyses were
described in Mas et al 2011 [28]. From the analysis, a total
of 57 bead types were found to be significant (p ≤ 0.001)
and differentially expressed after a moderate F test statisti-
cal assay. By linear contrast examination, fourteen beads
were found between G1 vs. G2, five beads between G2 vs.
G3, and fifty beads between G1 vs. G3. Agglomerative
hierarchical clustering analysis was performed by incor-
porating only the 50 beads differentially expressed
between G1 vs. G3. The analysis displayed two indepen-
dent groups composed by G1 or G3 samples. Interestingly,
G2 samples were found to be randomly associated within
both clusters may be reflecting a pathology miss-classifica-
tion component (Figure 4C). Gene ontology and gene
pathway analysis, using only those 50 beads, identified 9
gene-associated networks, whereas the top-scored was
involved in cellular development, infection mechanism,
and antigen presentation. The molecular and cellular func-
tion analysis associated those beads with cell-to-cell signal-
ing and interaction, cell death, cell morphology, and
carbohydrates metabolism. Interestingly, genes associated
with T cells biology such as IL-28RA, IL-28, suppressor of
T cell receptor signaling 1 (STS1), and CAP-GLY domain
containing linker protein 4 (CLIP4) were found to be
significantly increased in samples with predicted severe
fibrosis [28].
Yet, the mechanisms involved in HCV recurrence devel-
opment and progression are largely unknown. WGE ana-
lyses demonstrated to be a useful tool to either reveal the
HCV recurrence molecular biology, and to encourage the
identification of potential biomarkers to predict disease
severity. A set of no invasive biomarkers have been pro-
posed with promising results for the hepatic fibrosis pro-
gression assessment using specific peripheral blood serum
proteins as biomarkers [30-32]. Up today, the established
protein assay test demonstrated excellent utility for the
identification of HCV-advanced cirrhosis, but slighter
accuracy for earlier stages of the disease [32]. Thus, only
large cohort prospective studies in will contribute to opti-
mize the analytical performance of those tests. At mean-
time, liver biopsy remains to be the gold standard for
allograft fibrosis progression assessment in HCV recur-
rence despite its well-known no perfect accuracy [33-36].
The combined molecular markers detection and pathology
characterization, together with reliable clinical data col-
lected during the liver biopsy protocol may help to predict
the severity of HCV recurrence to come.
Overall comments
The accurate follow-up and the differential diagnosis of
post-transplant complications have been further struggled
by no reliable and difficult pathology reports, essentially in
post-transplanted HCV-infected patients [18]. However,
the implementation of WGE analyses permitted new
insights about the molecular biology characterization of
certain post-LT complications [13,23,28,37,38]. Further-
more, the extension of this technique to the follow-up of
HCV recurrence patients might permit the diagnosis and
surveillance of severity in the fibrosis progression, along
with pathological evaluation [28]. From this perspective, it
is imperative the continuous study of different molecular
aspects of mechanisms involved in HCV infection and
ACR. The complete understanding of the biological pro-
cess triggered in each condition will allow the identifica-
tion of early predictors for disease differentiation and
progression, and the implementation of them to the diag-
nostic arsenal. Importantly, it will impact directly in the
identification and treatment success rates.
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